KT A252
Alternative Names: KT-A252Latest Information Update: 16 Mar 2022
At a glance
- Originator Medical University of South Carolina
- Developer Kriya Therapeutics; Medical University of South Carolina
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Complement activation inhibitors; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 03 Feb 2022 Preclinical trials in Dry age-related macular degeneration in USA (Parenteral) as of February 2022
- 26 Jan 2022 Kriya Therapeutics and Medical University of South Carolina signs licensing agreement for complement targeting gene therapies for Eye disorders
- 26 Jan 2022 Medical University of South Carolina and Kriya Therapeutics plans a clinical trial in Dry age related macular degeneration